Xoft Intraoperative Radiation Therapy (IORT) for Brain Cancer: Local Tumor Control in Patients with Recurrent Glioblastoma

Previously Aired - May 14, 2020

  • Alexey Krivoshapkin, Head of Neurosurgery branch of Neurology and Neurosurgery School, MD, Professor, Neurosurgeon at the European Medical Center in Moscow, Russia
  • Alexey Gaytan, MD, PhD, Neurosurgeon at the European Medical Center in Moscow, Russia

Worldwide, almost 297,000 cases of brain and nervous system tumors are diagnosed per year.1 Glioblastoma is the most common and aggressive type of malignant primary brain tumor, with a median survival of 10-12 months.2,3 Treatment for GBM typically involves surgical removal, followed by radiation therapy or chemotherapy. There has been recent interest in intraoperative radiotherapy (IORT) as a potential treatment option for effective local tumor control. This approach is conceptually appealing because IORT allows for the delivery of a large, localized radiation dose to the tumor bed and the micro- and macroscopic tumor remnants in the vicinity of the surgical cavity. The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body. Learn more about the promising preliminary results of this procedure after GBM relapse. Join Professor Krivoshapkin & Dr. Gaytan for an informative product showcase discussing Neuro IORT and the benefits it offers to physicians, facilities and patients.

References:

  1. WHO, IARC, Globocan Cancer Incidence and Mortality Worldwide in 2018. Accessed via https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
  2. Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 8. Accessed via https://www.ncbi.nlm.nih.gov/books/NBK470003.
  3. Pan E, Prados MD. Glioblastoma Multiforme and Anaplastic Astrocytoma. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Accessed via https://www.ncbi.nlm.nih.gov/books/NBK12526/.

Please register for access to the webinar.

Lorem ipsum dolor sit amet

Ut Enim Minima

Sed ut perspiciatis unde omnis iste natus error sit voluptatem!

Quis Autem Vel

Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!

Quo Voluptas

Ut enim ad minima veniam, quis nostrum exercitationem ullam!

Speakers